1.14.14.86	(1E)-1-[4-(4-butyl-1H-1,2,3-triazol-1-yl)phenyl]-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol	-	39497	
1.14.14.86	(1E,3S)-1-(4-chlorophenyl)-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-3-ol	i.e. uniconazole	18925	
1.14.14.86	(2R,3R)-paclobutrazol	0.0045 mM, 50% inhibition	21737	
1.14.14.86	(2R,3R)-paclobutrazol	-	21737	
1.14.14.86	(2S,3S)-paclobutrazol	0.00025 mM, 50% inhibition	21738	
1.14.14.86	(2S,3S)-paclobutrazol	-	21738	
1.14.14.86	(5E)-6-tert-butyl-5-[(4-chlorophenyl)methylidene]-5,6-dihydro-8H-[1,2,4]triazolo[5,1-c][1,4]oxazine	-	222698	
1.14.14.86	(5E)-6-tert-butyl-5-[(4-nitrophenyl)methylidene]-5,6-dihydro-8H-[1,2,4]triazolo[5,1-c][1,4]oxazine	-	222699	
1.14.14.86	(E)-2-(2-((1-(4-(3-hydroxy-4,4-dimethyl-2-(1H-1,2,4-triazol-1-yl)pent-1-en-1-yl)phenyl)-1H-1,2,3-triazol-4-yl)methoxy)ethoxy)ethyl 4-methylbenzenesulfonate	i.e. abscinazole-E1, orUT1-E2Ts, or Abz-E1, a specific potent inhibitor of ABA 8'-hydroxylase, EC 1.14.13.93, but a weak inhibitor of CYP701A, both in vitro and in vivo	27990	
1.14.14.86	abscinazole-F1	-	41058	
1.14.14.86	CO	90% inhibition	176	
1.14.14.86	DSI-505ME	-	163007	
1.14.14.86	methyl (2E)-3-[1-[(1E)-1-(4-chlorophenyl)-3-hydroxy-4,4-dimethylpent-1-en-2-yl]-1H-imidazol-5-yl]prop-2-enoate	-	27987	
1.14.14.86	additional information	not inhibited by uniconazole-P	2	
1.14.14.86	additional information	among the azoles known as CYP51 inhibitors, ketoconazole, an antifungal medicine, is one of the most potent CYP51 inhibitor and forms a one-to-one complex with CYP51 as with uniconazole and CYP701B1. But ketoconazole does not bind and inhibit the purified ent-kaurene oxidase, CYP701B1; not inhibitory: ketoconazole	2	
1.14.14.86	paclobutrazol	-	124957	
1.14.14.86	paclobutrazol racemate	-	50187	
1.14.14.86	uniconazole	-	17692	
1.14.14.86	uniconazole	i.e. UNI	17692	
1.14.14.86	uniconazole	selective binding of CYP701B1 with uniconazole, is directly bound to the heme iron with its azole nitrogen	17692	
1.14.14.86	UT4	-	163006